By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BrainVectis 

18 route du Panorama

Fontenay-aux-Roses    92260  France
Phone: n/a Fax: n/a


SEARCH JOBS

BrainVectis' aim is to develop gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain. Based on work carried out by Dr. Nathalie Cartier-Lacave and her team at the UMR1169 unit (INSERM/CEA) and by her collaborators (INSERM/UMR-S 1130, UMR 8246-CNRS), BrainVectis is currently focusing on Huntington's disease and Alzheimer's disease, two serious and irreversible diseases for which as yet no effective treatment exists. BrainVectis is based in Fontenay aux Roses and has five employees. The company raised €1 million ($1.1m) in September 2016 in a series A round of financing.

YEAR FOUNDED:

2015

LEADERSHIP:

Founder and CEO: Jerome Becquart, PhD

Founder and CSO: Nathalie Cartier-Lacave, MD


Key Statistics


Email:
Ownership: Private

Web Site: BrainVectis
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Currently No News Articles
//-->